| Intervention | All Patients | Moderate-Severe Baseline Pain (WOMAC Pain Score 301–400 mm) | Mild Baseline Pain (WOMAC Pain Score 125–300) |
|---|---|---|---|
| Placebo | 60.1% | 54.3% | 61.7% |
| Celecoxib | 70.1% (p=0.008 vs. placebo) | 69.4% (p=0.06 vs. placebo) | 70.3% (p=0.04 vs. placebo) |
| Glucosamine | 64.0% (p=0.30 vs. placebo) | 65.7% (p=0.17 vs. placebo) | 63.6% (p=0.67 vs. placebo) |
| Chondroitin | 65.4% (p=0.17 vs. placebo) | 61.4% (p=0.39 vs. placebo) | 66.5% (p=0.27 vs. placebo) |
| Glucosamine + chondroitin | 66.6% (p=0.09 vs. placebo) | 79.2% (p=0.002 vs. placebo) | 62.9% (p=0.80 vs. placebo) |
GAIT = Glucosamine/chondroitin Arthritis Intervention Trial; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.